CASI Pharmaceuticals, Inc. (CASI) Financial Ratios
30 years of historical data (1995–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.3·High18.6
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
1.25
↓-80% vs avg
5yr avg: 6.39
30Y Low0.4·High23.5
ROE
↓
-301.8%
↑-207% vs avg
5yr avg: -98.3%
30Y Low-475%·High-14%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.0·High1.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CASI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
CASI Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $43M | $96M | $24M | $109M | $326M | $296M | $341M | $200M | $64M | $31M |
| Enterprise Value | $11M | $52M | $100M | $-21339056 | $75M | $272M | $245M | $258M | $158M | $39M | $27M |
| P/E Ratio → | -0.06 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.08 | 1.52 | 2.82 | 0.57 | 3.61 | 21.52 | 71.77 | — | — | — | 652.83 |
| P/B Ratio | 1.25 | 23.45 | 3.96 | 0.36 | 1.01 | 3.15 | 3.17 | 3.11 | 5.19 | 3.09 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CASI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.83 | 2.95 | -0.50 | 2.47 | 17.96 | 59.32 | — | — | — | 575.99 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | 4.07 | 3.81 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
CASI Profitability
Margins and return-on-capital ratios measuring operating efficiency
CASI Pharmaceuticals, Inc. earns an operating margin of -138.8%. Operating margins have compressed from -61.5% to -138.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -301.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 39.1% | 39.1% | 59.2% | 63.3% | 58.4% | 37.2% | 4.7% | — | — | — | 86.9% |
| Operating Margin | -138.8% | -138.8% | -74.0% | -61.5% | -137.6% | -348.6% | -968.1% | — | — | — | 14990.8% |
| Net Profit Margin | -137.6% | -137.6% | -79.5% | -95.1% | -121.5% | -318.9% | -1098.1% | — | — | — | -15104.0% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -301.8% | -301.8% | -59.1% | -46.9% | -34.7% | -49.0% | -44.7% | -37.1% | -36.3% | -128.7% | — |
| ROA | -60.9% | -60.9% | -31.4% | -35.0% | -27.6% | -41.9% | -42.0% | -34.7% | -29.6% | -56.4% | -84.1% |
| ROIC | -153.0% | -153.0% | -76.0% | -41.9% | -50.5% | -86.1% | -86.9% | -170.6% | — | — | — |
| ROCE | -104.6% | -104.6% | -36.4% | -25.9% | -33.9% | -49.2% | -39.2% | -35.4% | -32.4% | 60.4% | 94.3% |
CASI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $9M ($22M total debt minus $13M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 11.96 | 11.96 | 0.88 | 0.02 | 0.04 | 0.03 | 0.02 | 0.01 | 0.04 | 0.07 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 0.16 | 0.20 |
| Net Debt / Equity | — | 4.69 | 0.17 | -0.68 | -0.32 | -0.52 | -0.55 | -0.76 | -1.09 | -1.23 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -2.70 | -0.51 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -42.71 | -42.71 | — | -427.27 | — | — | — | -3345.93 | -718.16 | -278.62 | -86.40 |
CASI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.09x means CASI Pharmaceuticals, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 4.32x to 1.09x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.09 | 1.09 | 3.55 | 4.32 | 4.70 | 9.28 | 7.74 | 23.89 | 8.65 | 20.86 | 5.29 |
| Quick Ratio | 0.94 | 0.94 | 2.60 | 3.96 | 4.56 | 9.11 | 7.17 | 23.82 | 8.65 | 20.86 | 5.29 |
| Cash Ratio | 0.44 | 0.44 | 1.84 | 3.02 | 3.68 | 8.32 | 6.83 | 21.97 | 8.59 | 20.59 | 4.87 |
| Asset Turnover | — | 0.53 | 0.45 | 0.45 | 0.22 | 0.12 | 0.04 | — | — | — | 0.01 |
| Inventory Turnover | 3.31 | 3.31 | 0.87 | 2.58 | 6.58 | 7.01 | 0.87 | 5.90 | — | — | — |
| Days Sales Outstanding | — | 196.27 | 109.22 | 109.85 | 118.61 | 111.98 | 114.24 | — | — | — | — |
CASI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
CASI Pharmaceuticals, Inc. returns 31.1% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 31.1% | 1.7% | 0.8% | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.3% | 13.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 31.1% | 1.7% | 1.1% | 13.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $15M | $13M | $14M | $14M | $11M | $10M | $8M | $6M | $6M | $3M |
Peer Comparison
Compare CASI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CASIYou | $2M | -0.1 | — | — | 39.1% | -138.8% | -301.8% | -153.0% | — |
 ZLAB | $2B | -13.1 | — | — | 58.6% | -49.9% | -22.6% | -42.8% | — |
 LEGN | $5B | -9.0 | — | — | 60.3% | -13.3% | -29.1% | -12.7% | — |
 ZYME | $2B | -25.6 | 0.3 | — | 89.8% | -87.3% | -26.7% | -25.9% | 0.0 |
 CAN | $356M | -1.2 | — | — | 7.8% | -21.2% | -59.8% | -24.9% | — |
 HALO | $8B | 25.9 | 8.5 | 12.1 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 ACAD | $4B | 15.8 | 13.6 | 23.1 | 91.5% | 24.1% | 38.9% | 45.2% | 0.2 |
 SUPN | $3B | -75.7 | 54.1 | 64.4 | 89.6% | -5.1% | -3.7% | -2.8% | 0.8 |
 LXRX | $678M | -11.4 | — | — | 99.4% | -98.2% | -39.7% | -22.7% | — |
 MNKD | $1B | 178.0 | 27.5 | 80.1 | 82.5% | 11.1% | — | — | 1.2 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See CASI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CASI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CASI vs ZLAB
Side-by-side business, growth, and profitability comparison vs Zai Lab Limited.
Start ComparisonCASI — Frequently Asked Questions
Quick answers to the most common questions about buying CASI stock.
What is CASI Pharmaceuticals, Inc.'s P/E ratio?
CASI Pharmaceuticals, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is CASI Pharmaceuticals, Inc.'s ROE?
CASI Pharmaceuticals, Inc.'s return on equity (ROE) is -301.8%. The historical average is -144.9%.
Is CASI stock overvalued?
Based on historical data, CASI Pharmaceuticals, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is CASI Pharmaceuticals, Inc.'s dividend yield?
CASI Pharmaceuticals, Inc.'s current dividend yield is 31.10%.
What are CASI Pharmaceuticals, Inc.'s profit margins?
CASI Pharmaceuticals, Inc. has 39.1% gross margin and -138.8% operating margin.